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4adult ADHD
NL: 1.0 – 2.5 % (N= 1800) 
USA: 4.4 % (N= 3200)
(Nat. Comorbidity 
Survey Replication) 
worldwide: 3.4 % (N =11422)
(1.2 - 7.3%)
Kooij e.a. Psychol Med. 2005; 35: 817-27. 
Kessler e.a. Am J Psychiatry. 2006 Apr;163(4):716-23
Fayyad e.a. Br J Psychiatry. 2007; 190: 402-9
5Comorbidity in adults with ADHD
± 80 % of patients at least 1 
± 50 % at least 2 
comorbid psychiatric disorder(s):
- mood disorders: mood swings
depression
bipolar disorder
- anxiety disorders
- personality disorders
- Substance Use Disorders
McGough Am J Psychiatry 2005; 162: 1621-7
6substance use disorders (SUD)
main characteristic: loss of control
DSM-IV-TR : diagnostic and statistical manual of mental disorders
abuse: persistent use in spite of serious negative consequences
dependence: even more serious abuse, complicated by
• tolerance
• withdrawal symptomatology
craving
7Prevalence of Adult ADHD in Substance Abusers 
Seeking Treatment *
* Based on DSM-IV Criteria
*Based on DSM-IV Criteria
Author, Year Population ADHD
Levin, 1998 281 Cocaine Abusers 10-15%
Clure, 1999 136 Cocaine and/or Alcohol Abusers 15%
King, 1999 125 Methadone Patients 17%
Schubiner, 2000 201 Substance Abusers 24%
8Prevalence 
ADHD in SUD
Prevalence of ADHD in substance-abusing patients: 
A meta-analysis and meta-regression analysis.
Katelijne van Emmerik - van Oortmerssen
Geurt van de Glind
Wim van den Brink 
Filip Smit 
Cleo L. Crunelle
Robert A. Schoevers
29 studies, including 6689 subjects (4054 adolescents and 2635 adults)
Overall prevalence ADHD in SUD = 23.1% (95% C.I: 19.4% – 27.2%)
Meta-regression analysis:
- lower prevalence of ADHD in primary cocaine dependent subjects 
- higher prevalence of ADHD in studies with DICA or SADS-L
- no effect of age, gender, setting, time-frame, abstinence duration
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
Clark et al 0,286 0,216 0,368 -4,768 0,000
Garland et al 0,211 0,156 0,280 -6,933 0,000
Grella et al 0,130 0,110 0,152 -20,135 0,000
Hovens et al 0,310 0,200 0,447 -2,668 0,008
Jainchill et al 0,246 0,218 0,276 -13,889 0,000
Latimer et al 0,400 0,321 0,485 -2,308 0,021
de Milio 0,140 0,072 0,256 -4,756 0,000
Molina et al 0,286 0,244 0,333 -8,217 0,000
Novins et al 0,180 0,113 0,274 -5,496 0,000
Stowell et al 0,080 0,051 0,123 -9,961 0,000
Subramaniam etal A 0,330 0,243 0,431 -3,229 0,001
Subramaniam etal B 0,390 0,286 0,505 -1,877 0,061
Szobot et al 0,443 0,324 0,569 -0,888 0,374
Tarter et al 0,199 0,143 0,270 -6,832 0,000
Tims et al 0,380 0,342 0,420 -5,820 0,000
Carroll et al B 0,238 0,165 0,331 -4,980 0,000
Clure et al 0,150 0,099 0,220 -7,223 0,000
Daigre et al 0,200 0,126 0,302 -4,960 0,000
Falck et al 0,099 0,070 0,137 -11,669 0,000
Johann et al 0,213 0,171 0,262 -9,482 0,000
King et al 0,190 0,130 0,268 -6,360 0,000
Levin et al 0,100 0,070 0,141 -11,050 0,000
Modestin et al 0,110 0,062 0,187 -6,574 0,000
Ohlmeier et al A 0,231 0,156 0,328 -4,835 0,000
Ohlmeier et al B 0,541 0,416 0,661 0,640 0,522
Rounsaville et al 0,349 0,297 0,405 -5,130 0,000
Schubiner et al 0,240 0,186 0,304 -6,979 0,000
Tang et al 0,101 0,069 0,146 -10,269 0,000
Wood et al 0,330 0,181 0,523 -1,730 0,084
Ziedonis et al 0,346 0,291 0,405 -4,912 0,000
0,231 0,194 0,272 -10,677 0,000
-1,00 -0,50 0,00 0,50 1,00
Meta Analysis 0%-50%
9ADHD & SUD :  prevalence
bidirectional overrepresentation of ADHD and SUD 
among subjects with these disorders
ADHD prevalence clearly increased among SUD patients
clinical impression: ADHD prevalence even more increased 
among SUD populations with 
more severe / more chronic disorders (e.g. inpatient populations)
adults with ADHD + SUD are at risk for
other psychiatric comorbidities and 
a longer course of SUD 
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ADHD & SUD : selection of substances
substances used: EVERYTHING !
NO CLEAR SELECTION
not only psycho-stimulant drugs: 
amfetamines / cocaine
paradoxical effect of stimulant drugs : 
(some, not all) users become relaxed and more focused
also sedating substances: 
alcohol / heroine / soft drugs
Clure e.a. Am J Drug Alcohol Abuse. 1999; 25: 441-8
Biederman e.a. Am J Psychiatry 1995; 152: 1652-8
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ADHD & SUD :  case histories
patients with SUD and ADHD:
- more often a history of conduct disturbance in childhood
• Oppositional Defiant Disorder (ODD)
• Conduct Disorder (CD)
- more often an Antisocial Personality Disorder (ASP): 
up to 50 % of patients 
- earlier start of drug use/abuse
- more severe course of substance use disorder?
- ADHD not diagnosed or treated previously
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severity of
problematic
substance use
time
problem threshold
= loss of control
age of initiation
of drug use
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the earlier the age of initiation:
1. the more likely there is 
something fundamentally wrong:
- with the individual:
psychiatric disorders
- and/or with the environment: 
abuse, neglect
2. greater risk of
problematic substance use
Addictive drugs, primarily by virtue of neuroplastic changes associated with 
dopamine activity most highly concentrated in primary motivation circuitry, 
produce long-term motivational effects
Earlier age of initiation
is a strong predictor
of substance use disorders in adulthood
Chambers RA Am J Psychiatry 2003: 160: 1041-1052
McGue M Alcohol Clin Exp Res 2001; 25(8): 1156-1165
15
Influence of ADHD 
on initiation into, transition to and recovery from SUD 
ADHD accelerates transitions:
 earlier start of substance use
 more rapid transitions
use   abuse   dependance
nicotine   alcohol & softdrugs  harddrugs
 remission more difficult
Wilens e.a. J Nerv Ment Dis 1997; 185: 475-82
Wilens e.a. Am J Addiction 1998 7: 156-163
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ADHD & SUD : 
“… the increased association of ADHD and SUD is the product of a 
developmental interaction with ADHD symptoms (eg, impulsivity or 
behavior dysregulation) and the consequences of ADHD (eg, poor 
academic performance), creating an increased opportunity for the
development of a SUD.”
JJ Mariani & FR Levin, 2007
ADHD influences 
the development of problematic substance use 
at several levels 
Mariani JJ, Levin FR. American Journal on Addictions 2007; 16: 45-56
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ADHD & SUD : pathways of influence
ADHD SUD
ODD/CD ASP
Genetics
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ODD / CD / ASP and ADHD
severe conduct disorders in youth: 
• Oppositional Defiant Disorder (ODD)
• Conduct Disorder (CD)
Frequent + ADHD (up to 50 %)
well known risk factors for
• AntiSocial Personality Disorder (ASP)
• SUD
 for some experts MAJOR/ONLY explanation 
of ADHD-SUD-association
Lynskey & Hall Addiction 2001; 96: 815-22.
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ODD / CD / ASP and ADHD & SUD 
when controlling for the influence of these disorders 
in prevalence and longitudinal studies:
• SUD can be attributed to presence of ODD/CD/ASP
• influence of ADHD limited or absent
this combination of psychopathology (ADHD + CD/ASP +SUD)
is mostly found in patients
with severe/chronic substance use disorders
other studies have shown: 
1. ADHD is independant risk factor for SUD
2. combination of ADHD + CD highest risk for SUD  
(synergistic instead of additive effect)
Faraone Biol Psychiatry 2000; 48: 9-20.
Flory & Lynam Clin Child Fam Psychol Rev 2003; 6: 1-16. 
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Heredity
higher prevalence of SUD in ADHD families
ADHD symptoms more frequent
in families of SUD patients
is there an overlap in the genetic base
of ADHD and SUD ?
Dopamine receptor
Wilens Am J Addict 2005; 14: 179-87
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ADHD risk factors
• type of symptomatology
• risk  with hyperactivity/impulsivity
• severity of symptoms
• risk  with persistence of symptoms
• risk  more severe symptoms
• ADHD-related dysfunctions
• impulsivity / inability to delay gratification
• risky behaviour / no consideration of long-term consequences
• need for strong stimulation (boredom)
• psychological factors: self-medication hypothesis
• secundary problems: underachievement
demoralisation
low self-esteem
self-medication hypothesis (Khantzian) 
use of drugs in an attempt to influence / lessen / regulate 
psychiatric symptoms
The notion of “self-medication” is one of the most intuitively appealing 
theories about drug abuse. Drug abuse begins as a partially succesful 
attempt to assuage painful feelings. Individuals, predisposed by biological 
or psychological vulnerabilities find that drug effects corresponding to 
their particular problems are powerfully reinforcing. (R. M. Glass)
Problems are soluble in alcohol …
Problems are not dissolvable in alcohol, they can swim. 
(Heinz Ruhmann)
Khantzian Harv Rev Psychiatry 1997; 4: 231-44
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self-medication 
and ADHD
Drugs are used by ADHD 
patients: 
 to calm down
 to be able to think more clearly 
and to concentrate
 to lessen anxiety
 to feel less depressed
 to relieve boredom
 …
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Paradoxical calming effect 
of psychostimulant drugs in ADHD
paradoxical effect of amphetamine – speed :
is to be considered as: 
• important clinical clue for ADHD diagnosis
• predictor of positive response to stimulant medication
paradoxical effect of cocaine : less clear
• not easy to diffentiate any calming effect from strong euphoric effect 
of cocaine
• (probably) less predictive value
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Why treat ADHD 
in Substance Use Disorders (SUD)?
• ADHD is a risk factor for the development of 
substance use disorders, especially in combination 
with severe conduct disturbances in childhood 
(Conduct Disorder)
• ADHD is highly prevalent in patients with substance 
use disorders (prevalence 10 to 30%)
• ADHD has a negative influence on the prognosis of 
the substance use disorder
• earlier start drug use
• higher therapy drop-out rate
• higher relapse rate
• troublesome ADHD symptoms prevent an effective 
participation in treatment
Wilens, Psych Clinics of N America 2004; 27: 283-302
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Why treat ADHD 
in Substance Use Disorders ? 
to reverse the negative influence on SUD prognosis
ADHD treatment offers clear benefits to SUD patients
 stabilisation of psychiatric symptomatology
 self-medication hypothesis 
stabilisation of ADHD decreases the 
tendency to use drugs
 adequate executive functions are essential to a 
fruitful participation in treatment
sufficient reasons to recommend 
active screening for 
and treatment of ADHD !
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all new patients
screening 
instrument
diagnostic interview
• patiënt
• partner
• family
multimodular 
ADHD treatment
screening
assessment
treatment planning
possible ADHD 
diagnosis
confirmation of
ADHD diagnosis
ADHD in 10-30% 
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for a reliable
ADHD
diagnosis
a standard
procedure
is recommended
• interview patient 
• evaluate current and childhood symptomatology according to DSM-IV criteria 
DIVA: Diagnostic Interview for ADHD in adults: www.divacenter.eu
• seek corroborative information by partner/parents/siblings
• ask for school reports, earlier assessments and reports
• check family history
31
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the clinical picture
the clinical presentation of adults with ADHD is mostly inconspicuous but 
can offer clues for a positive diagnosis:
- physical restlessness is absent in most patients
- troublous and accelerated speech, loud voice
- unstructured and lengthy narrative
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ADHD 
diagnosis
is based primarily
on information regarding 
lifetime and current 
symptom presence and 
functioning, 
preferably from multiple 
sources (patient, partner, 
parents, family),
illustrating a chronic persistent
course,
and not on 
clinical symptom presentation
and not on 
neuropsychological testing
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Reliable diagnosis 
of ADHD 
in SUD patients
ADHD symptoms can be 
masked by effects drug use  
drug use can produce 
ADHD symptoms 
clinical assessment of ADHD in drug patients is difficult but not impossible:
ADHD = chronic disorder
evaluation of life-time symptomatology is needed
 Symptoms before start substance use 
 symptoms during periods of abstinence
 symptoms during periods of stable drug use
Mariani JJ, Levin FR. Am J Addict. 2007;16 Suppl 1:45-54
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trial treatment of possible ADHD 
In principle patients with ADHD have a specific response to 
psychostimulant medication, different from people without ADHD 
 trial treatment with MPH as a diagnostic procedure
TO BE AVOIDED
1. inaccurate diagnostic procedure
what looks like ADHD is only ADHD after a proper assessment
2. both false-positive and false-negative reactions to MPH are possible
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Diagnostic assessment
1. confirmation of ADHD diagnosis:
using information from all available sources:
 patient
 partner  severity of ADHD symptoms  & dysfunction
 family  symptomatology in childhood
2. assessment of substance use disorder (SUD)
3. psychiatric comorbidity: other psychiatric problems ? 
4. somatic problems ?
5. psychosocial problems ?
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Psychiatric Comorbidity
especially in patients with chronic and more severe addiction:
ADHD will be accompanied by:
- history of Conduct Disorder in youth
- other DSM-IV-TR Axis I comorbidity (mood and anxiety disorders)
- (antisocial) personality disorder
ADHD is certainly not the only psychiatric problem
ADHD is not even the most important problem
 Treatment efficacy of ADHD will be diminished 
due to the comorbid psychiatric disorders
Question: 
Why treat ADHD in these chronic and difficult patients? 
38
Why treat a minor disorder in complex patients ?
successful ADHD treatment can make a difference
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Integrated treatment planning
1. full assessment:
- psychiatric disorders
- medical disorders
- psychosocial problems
2. integrated treatment planning:
- treatment prioritisation: 
= treating the most important problem first
- treatment integration: 
≠ treating every disorder separately
= combining the different modules for the specific disorders 
in one coherent treatment
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Integrated treatment planning
1. informed consent: problem definition / diagnosis / 
treatment plan and restrictions
2. detoxification  abstinence
3. stabilisation: 
symptomatic (pharmacologic) treatment of psychiatric disorders
• DSM-IV-TR Axis I disorders (b.v. depression, anxiety disorder)
• treatment ADHD = medication
4. integrated treatment of substance use disorder
psychiatric comorbidity
• specific addiction treatment modules (e.g. relapse prevention)
• treatment personality disorder
• treatment ADHD = emphasis on medication compliance
5. rehabilitation - resocialisation: functioning in society
• treatment ADHD = coaching, cognitive therapy
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Does it work ?
stabilisation / remission of ADHD

stabilisation of mental state
improved ability to participate in treatment

stabilisation / remission of addiction
these suppositions:
 are partly confirmed by clinical experience
 are NOT yet supported by scientific evidence
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positive results of ADHD treatment
in case reports and open trials
+/-atomoxetinecocaine20
Levin, 
2009
+bupropionvarious14
Solhkah,
2005
+bupropioncocaine10
Levin, 
2002
+venlafaxine
alcohol
cocaine
10
Upadhyaya,
2001
+MPHcocaine10
Levin,
1998
Results
ADHD/SUD
InterventionDrug
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size
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disappointing results of RCTs 
in medical treatment of ADHD in SUD patients
--
atomoxetine
up to 100 mg
70
various
(adolescents)
Thurstone,
2010
--
MPH OROS
72 mg 
24
amphetamine
(outpatient)
Konstenius, 
2010
(+)+
atomoxetine
25 – 100 mg
80
alcohol
(outpatient)
Wilens,
2008
-/+?-
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106
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MPH 
2 x 20-40 mg SR
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medical treatment of ADHD in SUD patients
is compounded by several factors
1. diagnostic inaccuracy: no clear-cut ADHD patients
2. psychiatric comorbidity: 
• concurrent chronic psychiatric disorders 
• actual comorbidity 
3. neuroplastic changes  & adaptations in neurotransmitter systems 
due to chronic drug use
4. negative influence of persistent drug use
5. inadequate medication: use of immediate-release MPH
inadequate dosage
non-compliance 
6. substantial placebo response
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Predictors of a positive response 
on ADHD medication in SUD patients
- clear ADHD, i.e. mainly genetically based 
positive family history
- stable/limited comorbidity
treat comorbid Axis I disorders first
- abstinence or stable/limited drug use
no ADHD medication if patient is unable to control use
- use of modern medication and modern formulations
- good adherence to treatment
good motivation- concrete treatment goals
absent/limited personality dysfunction
experienced staff
ALL THERAPIES WORK BEST WITH THE BETTER PATIENTS
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Psychostimulant diversion and abuse
short-acting psychostimulants 
(methylphenidate, dextro-amphetamin) CAN BE ABUSED
dilemma: use of medication with clear risk of abuse
in patients who are liable to abuse psychotropic drugs?
euphoric effect only when used:
- in higher dosage
- intranasally/intravenously
case reports: abuse mainly by others, not by the patients
Kollins SH. J Clin Psychiatry. 2003;64 Suppl 11:14-8.
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Cocaine and Methylphenidate (COC and MPH)
Block the Dopamine Transporter
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coc or MPH
Cocaine 640 nM   MPH 390 nM
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PET Scans Show Cocaine and MPH Both Increase Perfusion in 
the Same Area of the Brain
Red color indicates increased perfusion
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Cocaine Shows More Rapid Pharmacokinetics
than Methylphenidate, 
Explaining the Binge Phenomenon with Cocaine
[11C]Cocaine [11C]Methylphenidate
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Drug in striatum
Volkow ND. Arch Gen Psychiatry. 1995; 52: 456-63
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Therapeutic use of methylphenidate
does not lead to abuse
Therapeutic use
 extracellular dopamine
in striatum
 concentration improvement
• low dosage
• peroral use
• slowly rising serum concentration 
 slow  dopamine
• aim: symptom reduction
• context: treatment
Abuse
 extracellular dopamine
in nucleus accumbens
 reinforcement of abuse
• higher dosage
• intranasally / intravenously
• rapidly rising serum concentration 
 rapid  dopamine
• aim: kick
• context: abuse
Volkow & Swanson, Am J Psychiatry 2003; 160; 1909-1918
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Safe use of psychostimulants
in ADHD & SUD patients 
Prevention of abuse is best !
Use of safe long-acting preparations
Methylphenidate:
long-acting preparations Concerta 12h duration of action
Equasym – Medikinet 8h
• available in Europe
• not affordable for most patients
Dexamphetamin:
prodrug lysdexamphetamin (Vyvance)
• available in the USA, not in Europe
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Lisdexamfetamine (Vyvance) 
lysdexamfetamine
= prodrug
lysine
dexamfetamine
no risk of abuse
gut
peroral
use
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Is safe use of short-acting psychostimulants possible 
in ADHD & SUD patients ?
short-acting psychostimulants should be considered a restricted option
in ADHD patients with substance use disorders,
to be used only under strict conditions: risk containment
 stick to your agreements: 
• target symptoms and therapy aims
• treatment conditions
stop medication when results are insufficient
or when conditions are not met
 most important condition = abstinence
if necessary control urine samples
 close monitoring of the patiënt, especially in the beginning
supervision of correct use of medication 
(contact pharmacist  / family  / partner / coach)
PRESCRIBE LIMITED SUPPLIES
 work actively on therapeutic relationship & therapy compliance
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Psychosocial treatment of ADHD in SUD
 psycho-education
 coaching
 cognitive therapy
clear benefit for adult ADHD patients
also beneficial for addicted ADHD patients in stable conditions:
- stable abstinence
- stabilisation/remission of ADHD symptoms
- psychiatric stability
Solanto MV. Am J Psychiatry. 2010 Aug;167(8):958-68.
Safren SA.  JAMA. 2010 Aug 25;304(8):875-80.
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Coaching & Cognitive therapy :  ingredients
1. psycho-education
2. training of organisational and attentional skills:
• planning & organisation
• time management
• structuring daily activities / housekeeping
• financial management
3. addressing negative/dysfunctional cognitions and beliefs:
• negative self-image
• avoidance of frustrating activities
4. re-orientation: learning to live with a chronic handicap
• work: retraining - occupational resettlement
5. emotional issues
• lost chances / failures / disappointments
• paying attention to family and relatives
6. group offers possibility of exchanging knowledge/experiences/emotions
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Will it work ?
Major challenge:
how to prove the benefit 
of multimodal treatment of ADHD in SUD patients
realistic expectations:
(compare with experience 
with other dual diagnosis patients) 
ADHD treatment:
- can lead to leads to 
stabilisation/remission of ADHD symptoms
- cannot and does not cure the addiction
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Greatest challenge: building the expertise
Adequate treatment of ADHD in addicted patients
demands a multimodular approach
executed by different team members: psychiatrist
psychologist
psychiatric nurse
ergotherapist
 high level of psychiatric expertise
 high level of therapeutic expertise
not always available in addiction treatment facilities
Treating ADHD in SUD patients
is a mark of quality psychiatric care !
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early diagnosis and treatment of ADHD  prevents SUD
(sensitisation: putative addiction threshold-lowering effect of 
psychostimulant medication in developing brain) 
Biederman, 1999: 56 children > 15 j, follow-up 4 j:
• medication treatment (mostly psychostimulant drugs) leads to 
decrease of SUD risk (85%)
Barkley, 2003: 147 children, follow-up 13 j into young adulthood (19-25 j):
• no indication for increase SUD with psychostimulant treatment
Wilens, 2003: meta-analysis: 6 studies, 674 patients:
• psychostimulant treatment of ADHD in youth leads to decrease in risk for SUD 
in adulthood
Biederman Pediatrics 1999; 104: e20
Barkley Pediatrics 2003; 111: 97-109
Wilens Pediatrics. 2003; 111: 179-85
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problematic
substance use
severity
time
problem threshold
= loss of control
age of initiation
of substance use
ADHD
treatment of
ADHD
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Protective effect of ADHD 
treatment not confirmed
in longer follow-up
explanation still lacking
inconsistent treatment: not all participants 
remained in active treatment
no evidence of increased risk of addiction 
following psychostimulant treatment in 
childhood
early identification and treatment of ADHD 
is still recommended
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Conclusions
ADHD is a frequently occuring and treatable (?) disorder in SUD patients
Treatment of ADHD in adults should always include screening for and 
treatment of SUD
Early detection and treatment of ADHD offers the best hope of preventing 
substance use disorders in adolescence and adulthood
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Conclusions
ADHD is a frequently occuring and treatable (?) disorder in SUD patients
The main challenge is to offer adequate and multimodal ADHD treatment 
in an integrated approach of these complex patients
ADHD treatment is a stimulus for improving the level 
of psychiatric care of SUD patients
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Conclusions
1. ADHD is an independant, treatable risk 
factor for SUD (of moderate influence).
2. Treatment of ADHD in adults should 
always include screening for and 
treatment of SUD. 
3. Screening for and treatment of ADHD 
deserves a prominent place in the 
integrated treatment of complex and 
severe substance use disorders.
